Skip to main content
SpringerLink
Log in

IAP Proteins and Their Therapeutic Potential

  • Chapter
  • First Online:
Cell Death

  • 2080 Accesses

Abstract

Precise regulation of cell death and survival is essential for proper maintenance of organismal homeostasis, development, and immune system. Deregulated cell death can lead to developmental defects, neuropathies, infections, and cancer. Inhibitor of apoptosis (IAP) proteins are evolutionarily conserved regulators of cell death with impact on numerous cellular processes. Initially identified as inhibitors of cell death during viral infection, IAP proteins block cell death by direct inhibition of apoptotic proteases (X chromosome-linked IAP) or by preventing caspase activation following death receptor engagement (cellular IAPs). Recently, the role of IAP proteins as ubiquitin ligases has emerged as a critical feature for their ability to modulate various signaling pathways (e.g., NF-κB, MAPK, NOD) and to influence cellular fate. In addition, IAP proteins are often overexpressed in human malignancies presenting them as attractive targets for anticancer therapy. Among the different strategies employed to target IAP proteins, IAP antagonists—small-molecule mimetics of the natural IAP antagonist SMAC—have garnered most attention. IAP antagonists have successfully passed initial safety scrutiny in clinical trials and are about to enter a critical phase in their development in which their antitumor efficacy will be tested in the hopes of providing novel treatments for cancer patients.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Varfolomeev E, Vucic D. Inhibitor of apoptosis proteins: fascinating biology leads to attractive tumor therapeutic targets. Future Oncol. 2011;7(5):633–48.

    PubMed  CAS  Google Scholar 

  2. Birnbaum MJ, Clem RJ, Miller LK. An apoptosis-inhibiting gene from a nuclear polyhedrosis virus encoding a polypeptide with Cys/His sequence motifs. J Virol. 1994;68(4):2521–8.

    PubMed  CAS  Google Scholar 

  3. Crook NE, Clem RJ, Miller LK. An apoptosis-inhibiting baculovirus gene with a zinc finger-like motif. J Virol. 1993;67(4):2168–74.

    PubMed  CAS  Google Scholar 

  4. Salvesen GS, Duckett CS. IAP proteins: blocking the road to death’s door. Nat Rev Mol Cell Biol. 2002;3(6):401–10.

    PubMed  CAS  Google Scholar 

  5. Salvesen GS, Abrams JM. Caspase activation - stepping on the gas or releasing the brakes? Lessons from humans and flies. Oncogene. 2004;23(16):2774–84.

    PubMed  CAS  Google Scholar 

  6. Ndubaku C, Cohen F, Varfolomeev E, Vucic D. Targeting inhibitor of apoptosis (IAP) proteins for therapeutic intervention [review]. Future Med Chem. 2009;1(8):1509–25.

    PubMed  CAS  Google Scholar 

  7. Vaux DL, Silke J. IAPs, RINGs and ubiquitylation. Nat Rev Mol Cell Biol. 2005;6(4):287–97.

    PubMed  CAS  Google Scholar 

  8. Blankenship JW, Varfolomeev E, Goncharov T, Fedorova AV, Kirkpatrick DS, Izrael-Tomasevic A, et al. Ubiquitin binding modulates IAP antagonist-stimulated proteasomal degradation of c-IAP1 and c-IAP2(1). Biochem J. 2009;417(1):149–60.

    PubMed  CAS  Google Scholar 

  9. Gyrd-Hansen M, Darding M, Miasari M, Santoro MM, Zender L, Xue W, et al. IAPs contain an evolutionarily conserved ubiquitin-binding domain that regulates NF-kappaB as well as cell survival and oncogenesis. Nat Cell Biol. 2008;10(11):1309–17.

    PubMed  CAS  Google Scholar 

  10. Chen Z, Naito M, Hori S, Mashima T, Yamori T, Tsuruo T. A human IAP-family gene, apollon, expressed in human brain cancer cells. Biochem Biophys Res Commun. 1999;264(3):847–54.

    PubMed  CAS  Google Scholar 

  11. Hauser HP, Bardroff M, Pyrowolakis G, Jentsch S. A giant ubiquitin-conjugating enzyme related to IAP apoptosis inhibitors. J Cell Biol. 1998;141(6):1415–22.

    PubMed  CAS  Google Scholar 

  12. Hofmann K, Bucher P, Tschopp J. The CARD domain: a new apoptotic signalling motif. Trends Biochem Sci. 1997;22(5):155–6.

    PubMed  CAS  Google Scholar 

  13. Jeyaprakash AA, Klein UR, Lindner D, Ebert J, Nigg EA, Conti E. Structure of a Survivin-Borealin-INCENP core complex reveals how chromosomal passengers travel together. Cell. 2007;131(2):271–85.

    PubMed  CAS  Google Scholar 

  14. Liston P, Roy N, Tamai K, Lefebvre C, Baird S, Cherton-Horvat G, et al. Suppression of apoptosis in mammalian cells by NAIP and a related family of IAP genes. Nature. 1996;379(6563):349–53.

    PubMed  CAS  Google Scholar 

  15. Wilmanski JM, Petnicki-Ocwieja T, Kobayashi KS. NLR proteins: integral members of innate immunity and mediators of inflammatory diseases. J Leukoc Biol. 2008;83(1):13–30.

    PubMed  CAS  Google Scholar 

  16. Hershko A, Ciechanover A. The ubiquitin system. Annu Rev Biochem. 1998;67:425–79.

    PubMed  CAS  Google Scholar 

  17. Pickart CM, Fushman D. Polyubiquitin chains: polymeric protein signals. Curr Opin Chem Biol. 2004;8(6):610–6.

    PubMed  CAS  Google Scholar 

  18. Malynn BA, Ma A. Ubiquitin makes its mark on immune regulation. Immunity. 2010;33(6):843–52.

    PubMed  CAS  Google Scholar 

  19. Deshaies RJ, Joazeiro CA. RING domain E3 ubiquitin ligases. Annu Rev Biochem. 2009;78:399–434.

    PubMed  CAS  Google Scholar 

  20. Reyes-Turcu FE, Ventii KH, Wilkinson KD. Regulation and cellular roles of ubiquitin-specific deubiquitinating enzymes. Annu Rev Biochem. 2009;78:363–97.

    PubMed  CAS  Google Scholar 

  21. Husnjak K, Dikic I. Ubiquitin-binding proteins: decoders of ubiquitin-mediated cellular functions. Annu Rev Biochem. 2012;81:291–322.

    PubMed  CAS  Google Scholar 

  22. Vucic D, Dixit VM, Wertz IE. Ubiquitylation in apoptosis: a post-translational modification at the edge of life and death. Nat Rev Mol Cell Biol. 2011;12(7):439–52.

    PubMed  CAS  Google Scholar 

  23. Dynek JN, Goncharov T, Dueber EC, Fedorova AV, Izrael-Tomasevic A, Phu L, et al. c-IAP1 and UbcH5 promote K11-linked polyubiquitination of RIP1 in TNF signalling. EMBO J. 2010;29(24):4198–209.

    PubMed  CAS  Google Scholar 

  24. Choi YE, Butterworth M, Malladi S, Duckett CS, Cohen GM, Bratton SB. The E3 ubiquitin ligase cIAP1 binds and ubiquitinates caspase-3 and -7 via unique mechanisms at distinct steps in their processing. J Biol Chem. 2009;284(19):12772–82.

    PubMed  CAS  Google Scholar 

  25. Hu S, Yang X. Cellular inhibitor of apoptosis 1 and 2 are ubiquitin ligases for the apoptosis inducer Smac/DIABLO. J Biol Chem. 2003;278(12):10055–60.

    PubMed  CAS  Google Scholar 

  26. Schile AJ, Garcia-Fernandez M, Steller H. Regulation of apoptosis by XIAP ubiquitin-ligase activity. Genes Dev. 2008;22(16):2256–66.

    PubMed  CAS  Google Scholar 

  27. Varfolomeev E, Blankenship JW, Wayson SM, Fedorova AV, Kayagaki N, Garg P, et al. IAP antagonists induce autoubiquitination of c-IAPs, NF-κB activation, and TNFα-dependent apoptosis. Cell. 2007;131(4):669–81.

    PubMed  CAS  Google Scholar 

  28. Varfolomeev E, Goncharov T, Fedorova AV, Dynek JN, Zobel K, Deshayes K, et al. c-IAP1 and c-IAP2 Are Critical Mediators of Tumor Necrosis Factor alpha (TNFα)-induced NF-κB Activation. J Biol Chem. 2008;283(36):24295–9.

    PubMed  CAS  Google Scholar 

  29. Bertrand MJ, Milutinovic S, Dickson KM, Ho WC, Boudreault A, Durkin J, et al. cIAP1 and cIAP2 facilitate cancer cell survival by functioning as E3 ligases that promote RIP1 ubiquitination. Mol Cell. 2008;30(6):689–700.

    PubMed  CAS  Google Scholar 

  30. Li X, Yang Y, Ashwell JD. TNF-RII and c-IAP1 mediate ubiquitination and degradation of TRAF2. Nature. 2002;416(6878):345–7.

    PubMed  Google Scholar 

  31. Varfolomeev E, Goncharov T, Maecker H, Zobel K, Komuves LG, Deshayes K, et al. Cellular inhibitors of apoptosis are global regulators of NF-kappaB and MAPK activation by members of the TNF family of receptors. Sci Signal. 2012;5(216):ra22.

    PubMed  Google Scholar 

  32. Vandenabeele P, Bertrand MJ. The role of the IAP E3 ubiquitin ligases in regulating pattern-recognition receptor signalling. Nat Rev Immunol. 2012;12:833–44.

    PubMed  CAS  Google Scholar 

  33. Steller H. Mechanisms and genes of cellular suicide. Science. 1995;267(5203):1445–9 [Research Support, Non-U.S. Gov’t Review].

    PubMed  CAS  Google Scholar 

  34. Vandenabeele P, Galluzzi L, Vanden Berghe T, Kroemer G. Molecular mechanisms of necroptosis: an ordered cellular explosion. Nat Rev Mol Cell Biol. 2010;11(10):700–14.

    PubMed  CAS  Google Scholar 

  35. Budihardjo I, Oliver H, Lutter M, Luo X, Wang X. Biochemical pathways of caspase activation during apoptosis. Annu Rev Cell Dev Biol. 1999;15:269–90.

    PubMed  CAS  Google Scholar 

  36. Kaufmann SH, Vaux DL. Alterations in the apoptotic machinery and their potential role in anticancer drug resistance. Oncogene. 2003;22(47):7414–30.

    PubMed  CAS  Google Scholar 

  37. Youle RJ, Strasser A. The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol. 2008;9(1):47–59.

    PubMed  CAS  Google Scholar 

  38. Riedl SJ, Salvesen GS. The apoptosome: signalling platform of cell death. Nat Rev Mol Cell Biol. 2007;8(5):405–13.

    PubMed  CAS  Google Scholar 

  39. Guicciardi ME, Gores GJ. Life and death by death receptors. FASEB J. 2009;23(6):1625–37.

    PubMed  CAS  Google Scholar 

  40. Peter ME, Krammer PH. The CD95(APO-1/Fas) DISC and beyond. Cell Death Differ. 2003;10(1):26–35.

    PubMed  CAS  Google Scholar 

  41. Micheau O, Tschopp J. Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes. Cell. 2003;114(2):181–90.

    PubMed  CAS  Google Scholar 

  42. Hsu H, Huang J, Shu HB, Baichwal V, Goeddel DV. TNF-dependent recruitment of the protein kinase RIP to the TNF receptor- 1 signaling complex. Immunity. 1996;4(4):387–96.

    PubMed  CAS  Google Scholar 

  43. Irmler M, Thome M, Hahne M, Schneider P, Hofmann K, Steiner V, et al. Inhibition of death receptor signals by cellular FLIP. Nature. 1997;388(6638):190–5.

    PubMed  CAS  Google Scholar 

  44. Kaufmann T, Strasser A, Jost PJ. Fas death receptor signalling: roles of Bid and XIAP. Cell Death Differ. 2012;19(1):42–50 [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t].

    PubMed  CAS  Google Scholar 

  45. Eckelman BP, Salvesen GS, Scott FL. Human inhibitor of apoptosis proteins: why XIAP is the black sheep of the family. EMBO Rep. 2006;7(10):988–94.

    PubMed  CAS  Google Scholar 

  46. Stennicke HR, Salvesen GS. Catalytic properties of the caspases. Cell Death Differ. 1999;6(11):1054–9.

    PubMed  CAS  Google Scholar 

  47. Shiozaki EN, Chai J, Rigotti DJ, Riedl SJ, Li P, Srinivasula SM, et al. Mechanism of XIAP-mediated inhibition of caspase-9. Mol Cell. 2003;11(2):519–27.

    PubMed  CAS  Google Scholar 

  48. Srinivasula SM, Hegde R, Saleh A, Datta P, Shiozaki E, Chai J, et al. A conserved XIAP-interaction motif in caspase-9 and Smac/DIABLO regulates caspase activity and apoptosis. Nature. 2001;410(6824):112–6.

    PubMed  CAS  Google Scholar 

  49. Chai J, Shiozaki E, Srinivasula SM, Wu Q, Dataa P, Alnemri ES, et al. Structural basis of caspase-7 inhibition by XIAP. Cell. 2001;104(5):769–80.

    PubMed  CAS  Google Scholar 

  50. Huang Y, Park YC, Rich RL, Segal D, Myszka DG, Wu H. Structural basis of caspase inhibition by XIAP: differential roles of the linker versus the BIR domain. Cell. 2001;104(5):781–90.

    PubMed  CAS  Google Scholar 

  51. Riedl SJ, Renatus M, Schwarzenbacher R, Zhou Q, Sun C, Fesik SW, et al. Structural basis for the inhibition of caspase-3 by XIAP. Cell. 2001;104(5):791–800.

    PubMed  CAS  Google Scholar 

  52. Du C, Fang M, Li Y, Li L, Wang X. Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell. 2000;102(1):33–42.

    PubMed  CAS  Google Scholar 

  53. Verhagen AM, Ekert PG, Pakusch M, Silke J, Connolly LM, Reid GE, et al. Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins. Cell. 2000;102(1):43–53.

    PubMed  CAS  Google Scholar 

  54. Liu Z, Sun C, Olejniczak ET, Meadows RP, Betz SF, Oost T, et al. Structural basis for binding of Smac/DIABLO to the XIAP BIR3 domain. Nature. 2000;408(6815):1004–8.

    PubMed  CAS  Google Scholar 

  55. Wu G, Chai J, Suber TL, Wu JW, Du C, Wang X, et al. Structural basis of IAP recognition by Smac/DIABLO. Nature. 2000;408(6815):1008–12.

    PubMed  CAS  Google Scholar 

  56. Vucic D, Franklin MC, Wallweber HJ, Das K, Eckelman BP, Shin H, et al. Engineering ML-IAP to produce an extraordinarily potent caspase 9 inhibitor: implications for Smac-dependent anti-apoptotic activity of ML-IAP. Biochem J. 2005;385(Pt 1):11–20.

    PubMed  CAS  Google Scholar 

  57. Eckelman BP, Salvesen GS. The human anti-apoptotic proteins cIAP1 and cIAP2 bind but do not inhibit caspases. J Biol Chem. 2006;281(6):3254–60.

    PubMed  CAS  Google Scholar 

  58. Shin H, Renatus M, Eckelman BP, Nunes VA, Sampaio CA, Salvesen GS. The BIR domain of IAP-like protein 2 is conformationally unstable: implications for caspase inhibition. Biochem J. 2005;385(Pt 1):1–10.

    PubMed  CAS  Google Scholar 

  59. Ma L, Huang Y, Song Z, Feng S, Tian X, Du W, et al. Livin promotes Smac/DIABLO degradation by ubiquitin-proteasome pathway. Cell Death Differ. 2006;13(12):2079–88.

    PubMed  CAS  Google Scholar 

  60. MacFarlane M, Merrison W, Bratton SB, Cohen GM. Proteasome-mediated degradation of Smac during apoptosis: XIAP promotes Smac ubiquitination in vitro. J Biol Chem. 2002;277(39):36611–6.

    PubMed  CAS  Google Scholar 

  61. Yang QH, Du C. Smac/DIABLO selectively reduces the levels of c-IAP1 and c-IAP2 but not that of XIAP and livin in HeLa cells. J Biol Chem. 2004;279(17):16963–70.

    PubMed  CAS  Google Scholar 

  62. Silke J, Kratina T, Chu D, Ekert PG, Day CL, Pakusch M, et al. Determination of cell survival by RING-mediated regulation of inhibitor of apoptosis (IAP) protein abundance. Proc Natl Acad Sci U S A. 2005;102(45):16182–7.

    PubMed  CAS  Google Scholar 

  63. Conze DB, Albert L, Ferrick DA, Goeddel DV, Yeh WC, Mak T, et al. Posttranscriptional downregulation of c-IAP2 by the ubiquitin protein ligase c-IAP1 in vivo. Mol Cell Biol. 2005;25(8):3348–56.

    PubMed  CAS  Google Scholar 

  64. Sun X, Yin J, Starovasnik MA, Fairbrother WJ, Dixit VM. Identification of a novel homotypic interaction motif required for the phosphorylation of receptor-interacting protein (RIP) by RIP3. J Biol Chem. 2002;277(11):9505–11.

    PubMed  CAS  Google Scholar 

  65. Cho YS, Challa S, Moquin D, Genga R, Ray TD, Guildford M, et al. Phosphorylation-driven assembly of the RIP1-RIP3 complex regulates programmed necrosis and virus-induced inflammation. Cell. 2009;137(6):1112–23.

    PubMed  CAS  Google Scholar 

  66. He S, Wang L, Miao L, Wang T, Du F, Zhao L, et al. Receptor interacting protein kinase-3 determines cellular necrotic response to TNF-alpha. Cell. 2009;137(6):1100–11.

    PubMed  CAS  Google Scholar 

  67. Vanlangenakker N, Vanden Berghe T, Bogaert P, Laukens B, Zobel K, Deshayes K, et al. cIAP1 and TAK1 protect cells from TNF-induced necrosis by preventing RIP1/RIP3-dependent reactive oxygen species production. Cell Death Differ. 2011;18(4):656–65 [Research Support, Non-U.S. Gov’t].

    PubMed  CAS  Google Scholar 

  68. Vandenabeele P, Declercq W, Van Herreweghe F, Vanden BT. The role of the kinases RIP1 and RIP3 in TNF-induced necrosis. Sci Signal. 2010;3(115):re4.

    PubMed  Google Scholar 

  69. Zhao J, Jitkaew S, Cai Z, Choksi S, Li Q, Luo J, et al. Mixed lineage kinase domain-like is a key receptor interacting protein 3 downstream component of TNF-induced necrosis. Proc Natl Acad Sci U S A. 2012;109(14):5322–7.

    PubMed  CAS  Google Scholar 

  70. Sun L, Wang H, Wang Z, He S, Chen S, Liao D, et al. Mixed lineage kinase domain-like protein mediates necrosis signaling downstream of RIP3 kinase. Cell. 2012;148(1–2):213–27.

    PubMed  CAS  Google Scholar 

  71. Wang Z, Jiang H, Chen S, Du F, Wang X. The mitochondrial phosphatase PGAM5 functions at the convergence point of multiple necrotic death pathways. Cell. 2012;148(1–2):228–43.

    PubMed  CAS  Google Scholar 

  72. Hayden MS, Ghosh S. Signaling to NF-kappaB. Genes Dev. 2004;18(18):2195–224.

    PubMed  CAS  Google Scholar 

  73. Scheidereit C. IκB kinase complexes: gateways to NF-κB activation and transcription. Oncogene. 2006;25(51):6685–705.

    PubMed  CAS  Google Scholar 

  74. Gentle IE, Silke J. New perspectives in TNF-R1-induced NF-kappaB signaling. Adv Exp Med Biol. 2011;691:79–88.

    PubMed  CAS  Google Scholar 

  75. Haas TL, Emmerich CH, Gerlach B, Schmukle AC, Cordier SM, Rieser E, et al. Recruitment of the linear ubiquitin chain assembly complex stabilizes the TNF-R1 signaling complex and is required for TNF-mediated gene induction. Mol Cell. 2009;36(5):831–44.

    PubMed  CAS  Google Scholar 

  76. Ikeda F, Deribe YL, Skanland SS, Stieglitz B, Grabbe C, Franz-Wachtel M, et al. SHARPIN forms a linear ubiquitin ligase complex regulating NF-kappaB activity and apoptosis. Nature. 2011;471(7340):637–41.

    PubMed  CAS  Google Scholar 

  77. Tokunaga F, Nakagawa T, Nakahara M, Saeki Y, Taniguchi M, Sakata S, et al. SHARPIN is a component of the NF-kappaB-activating linear ubiquitin chain assembly complex. Nature. 2011;471(7340):633–6.

    PubMed  CAS  Google Scholar 

  78. Gerlach B, Cordier SM, Schmukle AC, Emmerich CH, Rieser E, Haas TL, et al. Linear ubiquitination prevents inflammation and regulates immune signalling. Nature. 2011;471(7340):591–6.

    PubMed  CAS  Google Scholar 

  79. Walczak H. TNF and ubiquitin at the crossroads of gene activation, cell death, inflammation, and cancer. Immunol Rev. 2011;244(1):9–28 [Research Support, Non-U.S. Gov’t Review].

    PubMed  CAS  Google Scholar 

  80. Moulin M, Anderton H, Voss AK, Thomas T, Wong WW, Bankovacki A, et al. IAPs limit activation of RIP kinases by TNF receptor 1 during development. EMBO J. 2012;31(7):1679–91 [Research Support, Non-U.S. Gov’t].

    PubMed  CAS  Google Scholar 

  81. Varfolomeev E, Vucic D. (Un)expected roles of c-IAPs in apoptotic and NF-κB signaling pathways. Cell Cycle. 2008;7(11):1511–21.

    PubMed  CAS  Google Scholar 

  82. Dejardin E. The alternative NF-kappaB pathway from biochemistry to biology: pitfalls and promises for future drug development. Biochem Pharmacol. 2006;72(9):1161–79.

    PubMed  CAS  Google Scholar 

  83. Vallabhapurapu S, Matsuzawa A, Zhang W, Tseng PH, Keats JJ, Wang H, et al. Nonredundant and complementary functions of TRAF2 and TRAF3 in a ubiquitination cascade that activates NIK-dependent alternative NF-kappaB signaling. Nat Immunol. 2008;9(12):1364–70.

    PubMed  CAS  Google Scholar 

  84. Vince JE, Chau D, Callus B, Wong WW, Hawkins CJ, Schneider P, et al. TWEAK-FN14 signaling induces lysosomal degradation of a cIAP1-TRAF2 complex to sensitize tumor cells to TNFalpha. J Cell Biol. 2008;182(1):171–84.

    PubMed  CAS  Google Scholar 

  85. Gardam S, Turner VM, Anderton H, Limaye S, Basten A, Koentgen F, et al. Deletion of cIAP1 and cIAP2 in murine B lymphocytes constitutively activates cell survival pathways and inactivates the germinal center response. Blood. 2011;117:4041–51.

    PubMed  CAS  Google Scholar 

  86. Bertrand MJ, Doiron K, Labbe K, Korneluk RG, Barker PA, Saleh M. Cellular inhibitors of apoptosis cIAP1 and cIAP2 are required for innate immunity signaling by the pattern recognition receptors NOD1 and NOD2. Immunity. 2009;30(6):789–801 [Research Support, Non-U.S. Gov’t].

    PubMed  CAS  Google Scholar 

  87. Damgaard RB, Nachbur U, Yabal M, Wong WW, Fiil BK, Kastirr M, et al. The ubiquitin ligase XIAP recruits LUBAC for NOD2 signaling in inflammation and innate immunity. Mol Cell. 2012;46(6):746–58 [Research Support, Non-U.S. Gov’t].

    PubMed  CAS  Google Scholar 

  88. Lamkanfi M, Dixit VM. Modulation of inflammasome pathways by bacterial and viral pathogens. J Immunol. 2011;187(2):597–602 [Research Support, Non-U.S. Gov’t Review].

    PubMed  CAS  Google Scholar 

  89. Vince JE, Wong WW, Gentle I, Lawlor KE, Allam R, O’Reilly L, et al. Inhibitor of apoptosis proteins limit RIP3 kinase-dependent interleukin-1 activation. Immunity. 2012;36(2):215–27 [Research Support, Non-U.S. Gov’t].

    PubMed  CAS  Google Scholar 

  90. Fulda S, Vucic D. Targeting IAP proteins for therapeutic intervention in cancer. Nat Rev Drug Dis. 2012;11(2):109–24.

    CAS  Google Scholar 

  91. Ryan BM, O’Donovan N, Duffy MJ. Survivin: a new target for anti-cancer therapy. Cancer Treat Rev. 2009;35(7):553–62.

    PubMed  CAS  Google Scholar 

  92. Varfolomeev E, Moradi E, Dynek JN, Zha J, Fedorova AV, Deshayes K, et al. Characterization of ML-IAP protein stability and physiological role in vivo. Biochem J. 2012;447(3):427–36.

    PubMed  CAS  Google Scholar 

  93. Dynek JN, Chan SM, Liu J, Zha J, Fairbrother WJ, Vucic D. Microphthalmia-associated transcription factor is a critical transcriptional regulator of melanoma inhibitor of apoptosis in melanomas. Cancer Res. 2008;68(9):3124–32.

    PubMed  CAS  Google Scholar 

  94. Imoto I, Tsuda H, Hirasawa A, Miura M, Sakamoto M, Hirohashi S, et al. Expression of cIAP1, a target for 11q22 amplification, correlates with resistance of cervical cancers to radiotherapy. Cancer Res. 2002;62(17):4860–6.

    PubMed  CAS  Google Scholar 

  95. Imoto I, Yang ZQ, Pimkhaokham A, Tsuda H, Shimada Y, Imamura M, et al. Identification of cIAP1 as a candidate target gene within an amplicon at 11q22 in esophageal squamous cell carcinomas. Cancer Res. 2001;61(18):6629–34.

    PubMed  CAS  Google Scholar 

  96. Zender L, Spector MS, Xue W, Flemming P, Cordon-Cardo C, Silke J, et al. Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach. Cell. 2006;125(7):1253–67.

    PubMed  CAS  Google Scholar 

  97. Dierlamm J, Baens M, Wlodarska I, Stefanova-Ouzounova M, Hernandez JM, Hossfeld DK, et al. The apoptosis inhibitor gene API2 and a novel 18q gene, MLT, are recurrently rearranged in the t(11;18)(q21;q21)p6ssociated with mucosa- associated lymphoid tissue lymphomas. Blood. 1999;93(11):3601–9.

    PubMed  CAS  Google Scholar 

  98. Akagi T, Motegi M, Tamura A, Suzuki R, Hosokawa Y, Suzuki H, et al. A novel gene, MALT1 at 18q21, is involved in t(11;18) (q21;q21) found in low-grade B-cell lymphoma of mucosa-associated lymphoid tissue. Oncogene. 1999;18(42):5785–94.

    PubMed  CAS  Google Scholar 

  99. Morgan JA, Yin Y, Borowsky AD, Kuo F, Nourmand N, Koontz JI, et al. Breakpoints of the t(11;18)(q21;q21) in mucosa-associated lymphoid tissue (MALT) lymphoma lie within or near the previously undescribed gene MALT1 in chromosome 18. Cancer Res. 1999;59(24):6205–13.

    PubMed  CAS  Google Scholar 

  100. Isaacson PG. Update on MALT lymphomas. Best Pract Res Clin Haematol. 2005;18(1):57–68.

    PubMed  CAS  Google Scholar 

  101. Mehrotra S, Languino LR, Raskett CM, Mercurio AM, Dohi T, Altieri DC. IAP regulation of metastasis. Cancer Cell. 2010;17(1):53–64.

    PubMed  CAS  Google Scholar 

  102. Xu L, Zhu J, Hu X, Zhu H, Kim HT, LaBaer J, et al. c-IAP1 cooperates with Myc by acting as a ubiquitin ligase for Mad1. Mol Cell. 2007;28(5):914–22.

    PubMed  CAS  Google Scholar 

  103. Dogan T, Harms GS, Hekman M, Karreman C, Oberoi TK, Alnemri ES, et al. X-linked and cellular IAPs modulate the stability of C-RAF kinase and cell motility. Nat Cell Biol. 2008;10(12):1447–55.

    PubMed  CAS  Google Scholar 

  104. Oberoi-Khanuja TK, Karreman C, Larisch S, Rapp UR, Rajalingam K. Role of melanoma inhibitor of apoptosis (ML-IAP) protein, a member of the baculoviral IAP repeat (BIR) domain family, in the regulation of C-RAF kinase and cell migration. J Biol Chem. 2012;287(34):28445–55.

    PubMed  CAS  Google Scholar 

  105. Oberoi TK, Dogan T, Hocking JC, Scholz RP, Mooz J, Anderson CL, et al. IAPs regulate the plasticity of cell migration by directly targeting Rac1 for degradation. EMBO J. 2012;31(1):14–28 [Research Support, Non-U.S. Gov’t].

    PubMed  CAS  Google Scholar 

  106. LaCasse EC, Mahoney DJ, Cheung HH, Plenchette S, Baird S, Korneluk RG. IAP-targeted therapies for cancer. Oncogene. 2008;27(48):6252–75.

    PubMed  CAS  Google Scholar 

  107. Callies S, Andre V, Patel B, Waters D, Francis P, Burgess M, et al. Integrated analysis of preclinical data to support the design of the first in man study of LY2181308, a second generation antisense oligonucleotide. Br J Clin Pharmacol. 2011;71(3):416–28.

    PubMed  CAS  Google Scholar 

  108. Carrasco RA, Stamm NB, Marcusson EG, Sandusky GE, Iversen P, Patel BK. Antisense inhibition of survivin expression as a cancer therapeutic. Mol Cancer Ther. 2011;10:221–32.

    PubMed  CAS  Google Scholar 

  109. LaCasse EC, Cherton-Horvat GG, Hewitt KE, Jerome LJ, Morris SJ, Kandimalla ER, et al. Preclinical characterization of AEG35156/GEM 640, a second-generation antisense oligonucleotide targeting X-linked inhibitor of apoptosis. Clin Cancer Res. 2006;12(17):5231–41.

    PubMed  CAS  Google Scholar 

  110. Shaw TJ, Lacasse EC, Durkin JP, Vanderhyden BC. Downregulation of XIAP expression in ovarian cancer cells induces cell death in vitro and in vivo. Int J Cancer. 2008;122(6):1430–4 [Research Support, Non-U.S. Gov’t].

    PubMed  CAS  Google Scholar 

  111. Schimmer AD, Estey EH, Borthakur G, Carter BZ, Schiller GJ, Tallman MS, et al. Phase I/II trial of AEG35156 X-linked inhibitor of apoptosis protein antisense oligonucleotide combined with idarubicin and cytarabine in patients with relapsed or primary refractory acute myeloid leukemia. J Clin Oncol. 2009;27(28):4741–6 [Clinical Trial, Phase I Clinical Trial, Phase II Research Support, Non-U.S. Gov’t].

    PubMed  CAS  Google Scholar 

  112. Carter BZ, Mak DH, Morris SJ, Borthakur G, Estey E, Byrd AL, et al. XIAP antisense oligonucleotide (AEG35156) achieves target knockdown and induces apoptosis preferentially in CD34 + 38- cells in a phase 1/2 study of patients with relapsed/refractory AML. Apoptosis. 2011;16(1):67–74 [Clinical Trial, Phase I Clinical Trial, Phase II Multicenter Study Research Support, N.I.H., Extramural].

    PubMed  CAS  Google Scholar 

  113. Schimmer AD, Herr W, Hanel M, Borthakur G, Frankel A, Horst HA, et al. Addition of AEG35156 XIAP antisense oligonucleotide in reinduction chemotherapy does not improve remission rates in patients with primary refractory acute myeloid leukemia in a randomized phase II study. Clin Lymphoma Myeloma Leuk. 2011;11(5):433–8.

    PubMed  CAS  Google Scholar 

  114. Franklin MC, Kadkhodayan S, Ackerly H, Alexandru D, Distefano MD, Elliott LO, et al. Structure and function analysis of peptide antagonists of melanoma inhibitor of apoptosis (ML-IAP). Biochemistry. 2003;42(27):8223–31.

    PubMed  CAS  Google Scholar 

  115. Flygare JA, Fairbrother WJ. Small-molecule pan-IAP antagonists: a patent review. Expert Opin Ther Pat. 2010;20(2):251–67.

    PubMed  CAS  Google Scholar 

  116. Vucic D, Deshayes K, Ackerly H, Pisabarro MT, Kadkhodayan S, Fairbrother WJ, et al. SMAC Negatively Regulates the Anti-apoptotic Activity of Melanoma Inhibitor of Apoptosis (ML-IAP). J Biol Chem. 2002;277(14):12275–9.

    PubMed  CAS  Google Scholar 

  117. Fulda S, Wick W, Weller M, Debatin KM. Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo. Nat Med. 2002;8(8):808–15.

    PubMed  CAS  Google Scholar 

  118. Vucic D, Fairbrother WJ. The inhibitor of apoptosis proteins as therapeutic targets in cancer. Clin Cancer Res. 2007;13(20):5995–6000.

    PubMed  CAS  Google Scholar 

  119. Arnt CR, Chiorean MV, Heldebrant MP, Gores GJ, Kaufmann SH. Synthetic Smac/DIABLO peptides enhance the effects of chemotherapeutic agents by binding XIAP and cIAP1 in situ. J Biol Chem. 2002;277(46):44236–43.

    PubMed  CAS  Google Scholar 

  120. Li L, Thomas RM, Suzuki H, De Brabander JK, Wang X, Harran PG. A small molecule Smac mimic potentiates TRAIL- and TNFα-mediated cell death. Science. 2004;305(5689):1471–4.

    PubMed  CAS  Google Scholar 

  121. Sun H, Nikolovska-Coleska Z, Lu J, Meagher JL, Yang CY, Qiu S, et al. Design, synthesis, and characterization of a potent, nonpeptide, cell-permeable, bivalent Smac mimetic that concurrently targets both the BIR2 and BIR3 domains in XIAP. J Am Chem Soc. 2007;129(49):15279–94.

    PubMed  CAS  Google Scholar 

  122. Varfolomeev E, Alicke B, Elliott JM, Zobel K, West K, Wong H, et al. X chromosome-linked inhibitor of apoptosis regulates cell death induction by proapoptotic receptor agonists. J Biol Chem. 2009;284(50):34553–60.

    PubMed  CAS  Google Scholar 

  123. Gao Z, Tian Y, Wang J, Yin Q, Wu H, Li YM, et al. A dimeric Smac/diablo peptide directly relieves caspase-3 inhibition by XIAP. Dynamic and cooperative regulation of XIAP by Smac/Diablo. J Biol Chem. 2007;282(42):30718–27.

    PubMed  CAS  Google Scholar 

  124. Vince JE, Wong WW, Khan N, Feltham R, Chau D, Ahmed AU, et al. IAP antagonists target cIAP1 to induce TNFalpha-dependent apoptosis. Cell. 2007;131(4):682–93.

    PubMed  CAS  Google Scholar 

  125. Dueber EC, Schoeffler AJ, Lingel A, Elliott JM, Fedorova AV, Giannetti AM, et al. Antagonists induce a conformational change in cIAP1 that promotes autoubiquitination. Science. 2011;334(6054):376–80 [Research Support, N.I.H., Extramural Research Support, U.S. Gov’t, Non-P.H.S.].

    PubMed  CAS  Google Scholar 

  126. Feltham R, Bettjeman B, Budhidarmo R, Mace PD, Shirley S, Condon SM, et al. Smac mimetics activate the E3 ligase activity of cIAP1 protein by promoting RING domain dimerization. J Biol Chem. 2011;286(19):17015–28.

    PubMed  CAS  Google Scholar 

  127. Mace PD, Linke K, Feltham R, Schumacher FR, Smith CA, Vaux DL, et al. Structures of the cIAP2 RING domain reveal conformational changes associated with ubiquitin-conjugating enzyme (E2) recruitment. J Biol Chem. 2008;283(46):31633–40.

    PubMed  CAS  Google Scholar 

  128. Petersen SL, Wang L, Yalcin-Chin A, Li L, Peyton M, Minna J, et al. Autocrine TNFalpha signaling renders human cancer cells susceptible to smac-mimetic-induced apoptosis. Cancer Cell. 2007;12(5):445–56.

    PubMed  CAS  Google Scholar 

  129. Ndubaku C, Varfolomeev E, Wang L, Zobel K, Lau K, Elliott LO, et al. Antagonism of c-IAP and XIAP proteins is required for efficient induction of cell death by small-molecule IAP antagonists. ACS Chem Biol. 2009;4(7):557–66.

    PubMed  CAS  Google Scholar 

  130. Wu TY, Wagner KW, Bursulaya B, Schultz PG, Deveraux QL. Development and characterization of nonpeptidic small molecule inhibitors of the XIAP/caspase-3 interaction. Chem Biol. 2003;10(8):759–67.

    PubMed  CAS  Google Scholar 

  131. Schimmer AD, Welsh K, Pinilla C, Wang Z, Krajewska M, Bonneau MJ, et al. Small-molecule antagonists of apoptosis suppressor XIAP exhibit broad antitumor activity. Cancer Cell. 2004;5(1):25–35.

    PubMed  CAS  Google Scholar 

  132. Gonzalez-Lomicronpez M, Welsh K, Finlay D, Ardecky RJ, Ganji SR, Su Y, et al. Design, synthesis and evaluation of monovalent Smac mimetics that bind to the BIR2 domain of the anti-apoptotic protein XIAP. Bioorg Med Chem Lett. 2011;21(14):4332–6.

    Google Scholar 

  133. Stadel D, Mohr A, Ref C, MacFarlane M, Zhou S, Humphreys R, et al. TRAIL-induced apoptosis is preferentially mediated via TRAIL receptor 1 in pancreatic carcinoma cells and profoundly enhanced by XIAP inhibitors. Clin Cancer Res. 2010;16(23):5734–49 [Research Support, Non-U.S. Gov’t].

    PubMed  CAS  Google Scholar 

  134. Vogler M, Walczak H, Stadel D, Haas TL, Genze F, Jovanovic M, et al. Small molecule XIAP inhibitors enhance TRAIL-induced apoptosis and antitumor activity in preclinical models of pancreatic carcinoma. Cancer Res. 2009;69(6):2425–34 [Research Support, Non-U.S. Gov’t].

    PubMed  CAS  Google Scholar 

  135. Lu J, McEachern D, Sun H, Bai L, Peng Y, Qiu S, et al. Therapeutic potential and molecular mechanism of a novel, potent, nonpeptide, Smac mimetic SM-164 in combination with TRAIL for cancer treatment. Mol Cancer Ther. 2011;10(5):902–14 [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t].

    PubMed  CAS  Google Scholar 

  136. Jost PJ, Grabow S, Gray D, McKenzie MD, Nachbur U, Huang DC, et al. XIAP discriminates between type I and type II FAS-induced apoptosis. Nature. 2009;460(7258):1035–9.

    PubMed  CAS  Google Scholar 

  137. Flygare JA, Beresini M, Budha N, Chan H, Chan IT, Cheeti S, et al. Discovery of a potent small-molecule antagonist of inhibitor of apoptosis (IAP) proteins and clinical candidate for the treatment of cancer (GDC-0152). J Med Chem. 2012;55(9):4101–13.

    PubMed  CAS  Google Scholar 

Download references

Acknowledgment

The author thanks Wayne Fairbrother and Kurt Deshayes for critical reading of the manuscript and help with figures.

Author information

Authors and Affiliations

  1. Department of Early Discovery Biochemistry, Genentech, Inc., South San Francisco, CA, 94080, USA

    Domagoj Vucic

Authors
  1. Domagoj Vucic
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Domagoj Vucic .

Editor information

Editors and Affiliations

  1. Dept. of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts, USA

    Hao Wu

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer Science+Business Media New York

About this chapter

Cite this chapter

Vucic, D. (2014). IAP Proteins and Their Therapeutic Potential. In: Wu, H. (eds) Cell Death. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-9302-0_5

Download citation

Publish with us

Policies and ethics

Search

Navigation